THG · Hanover Insurance Group, Inc.
$213.23
+6.23 (+3.01%)
At close · Jul 17
Market Cap
$7.46B
Shares
34,986,787
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| John C. Roche | CEO | $10,486,571 |
| Jeffrey Farber | CFO | $4,548,532 |
| Richard W. Lavey | COO | $3,545,310 |
| Bryan Salvatore | President of Specialty Lines | $3,203,070 |
| Dennis F. Kerrigan | EVP, CLO and Corporate Secretary | $2,139,070 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| John C. Roche | CEO | $9,550,596 |
| Jeffrey Farber | CFO | $4,246,734 |
| Richard W. Lavey | — | $3,116,691 |
| Bryan Salvatore | President of Specialty Lines | $2,879,280 |
| Dennis F. Kerrigan | EVP, CLO and Corporate Secretary | $2,031,703 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| John C. Roche | CEO | $7,721,129 |
| Jeffrey Farber | CFO | $3,499,209 |
| Richard W. Lavey | — | $2,422,676 |
| Bryan Salvatore | President of Specialty Lines | $2,272,558 |
| Dennis F. Kerrigan | EVP, CLO and Corporate Secretary | $1,637,829 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| John C. Roche | CEO | $6,826,023 |
| Jeffrey Farber | CFO | $3,239,035 |
| Richard W. Lavey | — | $2,174,482 |
| Bryan Salvatore | President of Specialty Lines | $1,998,471 |
| Dennis F. Kerrigan | EVP, CLO and Corporate Secretary | $1,525,203 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| John C. Roche | CEO | $6,773,668 |
| Jeffrey Farber | CFO | $3,345,351 |
| Richard W. Lavey | — | $2,086,591 |
| Bryan Salvatore | President of Specialty Lines | $1,899,921 |
| Dennis F. Kerrigan | EVP, CLO and Corporate Secretary | $1,591,830 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| John C. Roche | CEO | $6,234,413 |
| Jeffrey Farber | CFO | $3,427,714 |
| Richard W. Lavey | — | $2,033,779 |
| Bryan Salvatore | President of Specialty Lines | $1,897,428 |
| Dennis F. Kerrigan | General Counsel | $1,742,080 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| John C. Roche | CEO | $4,979,777 |
| Jeffrey Farber | CFO | $2,957,596 |
| J. Kendall Huber | General Counsel | $1,994,860 |
| Richard W. Lavey | — | $1,721,356 |
| Agency Markets | — | $1,721,356 |
| Bryan Salvatore | President of Specialty Lines | $1,600,152 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| John C. Roche | CEO | $4,168,271 |
| Jeffrey Farber | CFO | $2,953,263 |
| J. Kendall Huber | General Counsel | $2,034,299 |
| Richard W. Lavey | — | $1,586,469 |
| Agency Markets | — | $1,586,469 |
| Bryan Salvatore | President of Specialty Lines | $1,453,001 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Jeffrey Farber | CFO | $2,617,388 |
| John C. Roche | CEO | $2,011,343 |
| Bryan Salvatore | President of Specialty Lines | $1,831,259 |
| J. Kendall Huber | General Counsel | $1,709,483 |
| Agency Markets | — | $1,322,619 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Richard W. Lavey | member of the Board of Directors | Appointed | 2026-07-15 |
| John C. Roche | member of the Board of Directors | Retired | 2026-07-15 |
| John C. Roche | President and Chief Executive Officer | Retired | 2026-07-15 |
| Patricia A. Norton-Gatto | Principal Accounting Officer | Appointed | 2026-05-13 |
Key facts
CIK
944695
CUSIP
410867105
13F (30d)
72 filings
71 filers
Visit website
Investor relations